Cardio Diagnostics Holdings Inc (CDIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cardio Diagnostics Holdings Inc (CDIO) has a cash flow conversion efficiency ratio of -0.195x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.36 Million) by net assets ($6.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cardio Diagnostics Holdings Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Cardio Diagnostics Holdings Inc - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Cardio Diagnostics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cardio Diagnostics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardio Diagnostics Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Induct AS
OL:INDCT
|
N/A |
|
BetterLife Pharma Inc
F:NPAU
|
0.030x |
|
Strike Resources Ltd
AU:SRK
|
-0.102x |
|
Nippon Active Value Fund Plc
LSE:NAVF
|
0.005x |
|
Adalta Ltd
AU:1AD
|
2.240x |
|
Gencell Ltd
TA:GNCL
|
-0.577x |
|
Custodian REIT PLC
LSE:CREI
|
0.025x |
|
5E ADVANCED MATERIALS CDI
F:J9I0
|
-0.101x |
Annual Cash Flow Conversion Efficiency for Cardio Diagnostics Holdings Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Cardio Diagnostics Holdings Inc from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Cardio Diagnostics Holdings Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.97 Million | $-5.73 Million | -0.821x | -57.20% |
| 2024-12-31 | $9.56 Million | $-4.99 Million | -0.522x | +72.76% |
| 2023-12-31 | $2.96 Million | $-5.67 Million | -1.917x | -62.02% |
| 2022-12-31 | $4.30 Million | $-5.09 Million | -1.183x | -115.97% |
| 2021-12-31 | $1.07 Million | $-585.29K | -0.548x | -227.92% |
| 2020-12-31 | $60.37K | $25.86K | 0.428x | -- |
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart dise… Read more